Press ReleaseNicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma Denali Phase 3 co-funded equally by Nicox and Ocumension TherapeuticsPhase
Press ReleaseNicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical DevelopmentDecember 13, 2021- release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext
Press ReleaseNicox's Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease A subgroup of patients in the Phase 2b Mississippi clinical trial
Press ReleaseNicox Provides Third Quarter 2021 Business and Financial Highlights VYZULTA and ZERVIATE prescriptions in the U.S. increased by 35% and 213% respectively in Q3 2021 compared
Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update
Lead value drivers are 100% ownership of NCX 470 and NCX 4251 in the U.S
.
21
C
sufficient for the Company to
meet its current requirements for the next twelve months July 16, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, provided business and financial highlights for Q2 2021 for Nicox SA and its subsidiaries (the Nicox Group ) as well as an update on its strategy and key expected value-inflection milestones today.
timely
NCX 4251
etain the full revenue poten
tial from
in the U.S.